Product image of Itovebi (Inavolisib) supplied by GNH India

Itovebi

Active Ingredient:
Inavolisib
Origin:
EU

Itovebi (Inavolisib)

Inavolisib, the active ingredient in Itovebi, is a PI3K inhibitor presented as an oral formulation for oral use. It targets the PI3K/AKT signaling pathway and is investigated for the treatment of certain solid tumours in adult oncology patients.

GNH India supplies Itovebi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards, provides regulatory‑approved batches for clinical and commercial use, and ensures consistent product availability.

Manufacturer / TM Owner

Roche Registration Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Itovebi acts on the PI3K/AKT pathway and is evaluated in oncology settings.

  • PIK3CA‑mutated breast cancer: improves disease control when combined with endocrine therapy.
  • Advanced solid tumours with PI3K pathway activation: used in clinical trials to assess tumor response.
  • Hormone receptor‑positive metastatic breast cancer: studied as part of combination regimens to extend progression‑free survival.

How It Works

  • Inavolisib selectively inhibits the PI3Kα isoform, blocking the PI3K/AKT signaling cascade that drives cell proliferation and survival. By preventing downstream AKT phosphorylation, the drug reduces oncogenic signaling, leading to tumor cell growth arrest and apoptosis in cancers dependent on PI3Kα activity.

Side Effects

Adverse reactions have been observed in clinical studies of Inavolisib.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: frequent loose stools.
  • Fatigue: reduced energy levels.
  • Decreased appetite: reduced food intake.
  • Hyperglycemia: elevated blood glucose levels.
  • Rash: skin irritation or erythema.

Serious or Rare Side Effects

  • Severe hyperglycemia: may require medical intervention.
  • Pneumonitis: inflammation of lung tissue.
  • Hepatic toxicity: significant liver enzyme elevation.
  • Interstitial lung disease: rare pulmonary complications.
  • Stevens‑Johnson syndrome: severe skin reaction.
  • Thrombocytopenia: marked reduction in platelet count.

Precautions & Warnings

Safety considerations should be observed before and during treatment with Itovebi.

  • Monitor blood glucose: patients may develop hyperglycemia.
  • Assess liver function: risk of hepatic enzyme elevation.
  • Evaluate for infections: immunosuppression can increase infection risk.
  • Avoid use in uncontrolled diabetes: may exacerbate glycemic control.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Potential drug interactions require careful management.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase Inavolisib exposure.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect.
  • Antidiabetic agents: concurrent use may necessitate dose adjustment due to hyperglycemia risk.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise plasma levels.

  • Antacids containing aluminum or magnesium: could affect oral absorption.
  • Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for myopathy.

Frequently Asked Questions

Itovebi contains Inavolisib, a PI3Kα inhibitor that is being studied for the treatment of certain solid tumours, particularly PIK3CA‑mutated breast cancer and other cancers driven by the PI3K/AKT pathway.

Inavolisib selectively blocks the PI3Kα isoform, preventing activation of the downstream AKT signaling cascade. This interruption reduces tumor cell proliferation and promotes apoptosis in cancers that rely on PI3Kα signaling.

The prescribed dose of Itovebi is determined by the treating physician based on the patient’s clinical condition, disease stage, and other therapeutic considerations. Dosage regimens are not standardized and must follow the prescriber’s instructions.

Safety data for Itovebi in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Itovebi, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itovebi (Inavolisib) is a selective PI3Kα inhibitor, offering a more targeted approach compared with pan‑PI3K inhibitors that affect multiple isoforms. This selectivity may result in a different safety profile and efficacy pattern, especially in tumors harboring PIK3CA mutations.

Itovebi should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight to maintain product stability.

Itovebi is administered orally as directed by the prescribing clinician. The tablet (or capsule) is swallowed whole with water, and dosing schedules are individualized based on the treatment plan.

Serious risks include severe hyperglycemia, pneumonitis, hepatic toxicity, interstitial lung disease, Stevens‑Johnson syndrome, and significant thrombocytopenia. Patients should be monitored regularly for these events, and treatment should be discontinued if they occur.

Itovebi is contraindicated in patients with uncontrolled diabetes, severe hepatic impairment, or known hypersensitivity to Inavolisib or any excipients. It should also be avoided in individuals taking strong CYP3A4 inhibitors or inducers without medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Inavolisib

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT